Programmed death ligand 1 (PDL1), widely expressed on the surface of dendritic cells, B-cells, and multiple tumor cells, including breast cancer, has been associated with large tumor size, high grade, high proliferation, HER-2-positive status, leading to a poorer clinical outcome [52,53]. The gene discussed is ERBB2; the disease is breast carcinoma.